Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 18.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 18.5 Contact Hours.

Acknowledgment of Support

This activity is supported by Physicians Education Resource

2021 Annual Psychiatric Times™ World CME Conference™

Release Date: October 20, 2021
Expiration Date: October 20, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in the field of psychiatry in a multiday conference. The evolution in treating psychiatric disease continues with discoveries in imaging and genomic profiling and the investigation of novel molecules to manage prevalent mental, emotional, and behavioral disorders. Psychiatrists and other members of the multidisciplinary care team must understand and appreciate the latest clinical developments and optimal methods to apply that knowledge in clinical practice. The 2021 Annual Psychiatric Times World CME Conference™ showcases expert presentations and panel discussions of best practice for managing challenging psychiatric diagnoses, including major depressive disorder, substance use disorders, bipolar disorder, and schizophrenia, as well as mental health initiatives that target special populations.

This educational activity is an archive of the live virtual symposium held from September 30 to October 2, 2021.

Acknowledgement of Commercial Support

This activity is supported by Physicians Education Resource
 

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This activity is directed toward psychiatrists and other health care professionals interested in the diagnosis and management of patients with psychiatric disorders.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss appropriate screening and diagnostic approaches for psychiatric disorders
  • Describe current strategies and recent advances in treating psychiatric disorders
  • Explain the mechanism of action of therapeutic agents used to treat psychiatric disorders
  • Identify strategies to manage treatment-related adverse events in patients given a diagnosis of psychiatric disorders
  • Describe the impact of psychiatric conditions on patients’ and caregivers’ quality of life
  • Outline multidisciplinary care strategies to optimize outcomes for patients affected by psychiatric disorders and their caregivers

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
 

Program Co-Chairs

Anita Clayton, MD
Anita Clayton, MD
David C. Wilson Professor and Chair
Department of Psychiatry and Neurobehavioral Sciences
Professor, Clinical Obstetrics and Gynecology
University of Virginia
Charlottesville, VA

Disclosures: Grant Research Support: Janssen Pharmaceuticals, Relmada Therapeutics, Sage Therapeutics; Consultant: Acadia Pharmaceuticals, Alkermes, Allergan, AMAG Pharmaceuticals, Astellas Pharma, Fabre-Kramer Pharmaceuticals, MedAvante-ProPhase, Ovoca Bio, PureTech Health, S1 Biopharma, Sage Therapeutics, Takeda Pharmaceutical Company/Lundbeck, WCG Clinical; Shareholder: Euthymics Bioscience, Mediflix, S1 Biopharma.

 
John J. Miller, MD
John J. Miller, MD
Medical Director, Brain Health Website
Editor-in-Chief, Psychiatric Times™
Staff Psychiatrist, Seacoast Mental Health Center
Consulting Psychiatrist, Exeter Hospital
Exeter, NH
Consulting Psychiatrist, Insight Meditation Society
Barre, MA

Disclosures: Consultant: Janssen Ph.armaceuticals, Sunovion Pharmaceuticals; Speakers’ Bureau: Allergan, Intra-Cellular Therapies, Neurocrine Biosciences, Otsuka Pharmaceutical, Sunovion Pharmaceuticals, Teva Pharmaceuticals.

Sanjai Rao, MD
Sanjai Rao, MD
Associate Clinical Professor of Psychiatry
University of California, San Diego
Associate Training Director
VA San Diego Healthcare System
San Diego, CA

Disclosures: Consultant: Alkermes, Janssen Pharmaceuticals; Speakers’ Bureau: Alkermes, Neurocrine Biosciences, Janssen Pharmaceuticals, Otsuka Pharmaceutical Co, Sunovion Pharmaceuticals.

Faculty

Linda L. Carpenter, MD
Linda L. Carpenter, MD
Professor, Department of Psychiatry and Human Behavior
Chief, Mood Disorders Program
Butler Hospital
Alpert Medical School
Brown University
Providence, RI

Disclosures: Grant Research Support: Affect Neuro, Janssen Pharmaceuticals, Neurolief, National Institutes of Health, Neuronetics; Consultant: Neuronetics, Nexstim, Neurolief, Otsuka Pharmaceutical Co, Sage Therapeutics, Sunovion Pharmaceuticals; Other: Nexstim (research equipment).

Christoph U. Correll, MD
Christoph U. Correll, MD
Professor of Psychiatry and Molecular
Medicine
Donald and Barbara Zucker School of
Medicine at Hofstra/Northwell
Hempstead, NY

Disclosures: Grant Research Support: Takeda Pharmaceutical Company; Consultant: Acadia Pharmaceuticals, Alkermes, Allergan, Angelini Pharma, Axsome Therapeutics, Gedeon Richter, Gerson Lehrman Group, Intra-Cellular Therapies, Janssen Pharmaceuticals/Johnson & Johnson, LB Pharmaceuticals, Lundbeck, MedAvante-ProPhase, Medscape, Neurocrine Biosciences, Noven Pharmaceuticals, Otsuka Pharmaceutical Co, Pfizer, Recordati Rare Diseases, Rovi, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Takeda Pharmaceutical Company, Teva Pharmaceuticals; Shareholder: LB Pharma.

Itai Danovitch, MD, MBA, FAPA, DFASAM
Itai Danovitch, MD, MBA, FAPA, DFASAM
Chair, Department of Psychiatry and Behavioral Neurosciences
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosures: Shareholder: Bexson Biomedical, Science 37, Workit Health; Other: Bexson Biomedical (board of directors).

Melissa P. DelBello, MD, MS
Melissa P. DelBello, MD, MS
Co-Medical Director, Mood Disorders Center
Dr Stanley and Mickey Kaplan Professor and Chair, Psychiatry & Behavioral Neuroscience
University of Cincinnati
Cincinnati, OH

Disclosures: Grant Research Support: Acadia Pharmaceuticals, Allergen, Janssen Pharmaceuticals, Johnson & Johnson, Lundbeck, Otsuka Pharmaceutical Co, Pfizer, Sunovion Pharmaceuticals, Supernus Pharmaceuticals; Speakers’ Bureau: Alkermes, Allergan, Assurex Global, CMEology, Johnson & Johnson, Lundbeck, Neuronetics, Otsuka Pharmaceutical Co, Pfizer, Sunovion Pharmaceuticals, Supernus Pharmaceuticals.

Rick Doblin, PhD
Rick Doblin, PhD
Founder and Executive Director
Multidisciplinary Association for Psychedelic Studies (MAPS)
San Jose, CA
Carl Fleisher, MD
Health Sciences Assistant Clinical Professor of Psychiatry
UCLA Health
Los Angeles, CA

Disclosures: Rick Goblin, PhD, has no relevant financial relationships with ineligible companies.

Carl Fleisher, MD
Carl Fleisher, MD
Assistant Clinical Professor, Department of Psychiatry and Biobehavioral Sciences
University of California, Los Angeles
Los Angeles, CA

Disclosures: Shareholder: Reflect.

Nassir Ghaemi, MD, MPH
Nassir Ghaemi, MD, MPH
Professor, Psychiatry and Pharmacology
Tufts University School of Medicine
Clinical Lecturer, Psychiatry
Cambridge Health Alliance
Harvard Medical School
Boston, MA

Disclosures: Nassir Ghaemi, MD, MPH, has no relevant financial relationships with ineligible companies.

Joseph F. Goldberg, MD
Joseph F. Goldberg, MD
Clinical Professor, Psychiatry
Mount Sinai Health System
New York, NY

Disclosures: Joseph F. Goldberg, MD, has no relevant financial relationships with ineligible companies.

Christopher J. Hammond, MD, PhD
Christopher J. Hammond, MD, PhD
Assistant Professor, Psychiatry and Behavioral Sciences
Johns Hopkins Medicine
Baltimore, MD

Disclosures: Christopher J. Hammond, MD, PhD, has no relevant financial relationships with ineligible companies.

Alana Iglewicz, MD
Alana Iglewicz, MD
Associate Training Director, Psychiatry
Assistant Clinical Professor, Psychiatry
University of California, San Diego School of Medicine
San Diego, CA

Disclosures: Alana Iglewicz, MD, has no relevant financial relationships with ineligible companies.

James Knoll, MD
James Knoll, MD
Clinical Professor, Psychiatry and Behavioral Sciences
State University of New York Upstate Medical University
Syracuse, NY

Disclosures: James Knoll, MD, has no relevant financial relationships with ineligible companies.

Carla Marienfeld, MD
Carla Marienfeld, MD
Health Sciences Clinical Professor, Psychiatry
University of California, San Diego
La Jolla, CA

Disclosures: Carla Marienfeld, MD, has no relevant financial relationships with ineligible companies.

Nidal Moukaddam, MD, PhD
Nidal Moukaddam, MD, PhD
Associate Professor, Psychiatry and Behavioral Sciences
Baylor College of Medicine
Houston, TX

Disclosures: Nidal Moukaddam, MD, has no relevant financial relationships with ineligible companies.

Richard Lawrence (Larry) Merkel Jr, MD, PhD
Richard Lawrence (Larry) Merkel Jr, MD, PhD
Associate Professor, Psychiatric Medicine
Director of Outreach
Department of Psychiatry and Neurobehavioral Sciences
University of Virginia
Charlottesville, VA

Disclosures: Richard Lawrence (Larry) Merkel Jr., MD, PhD, has no relevant financial relationships with ineligible companies.

John J. Miller, MD
John J. Miller, MD
Medical Director, Brain Health
Editor –in Chief, Psychiatric Times®
Staff Psychiatrist, Seacoast Mental Health Center
Consulting Psychiatrist, Exeter Hospital
Exeter, NH
Psychiatric Consultant, Insight Meditation Society
Barre, MA

Disclosures: Consultant: Janssen Pharmaceuticals, Sunovion Pharmaceuticals; Speakers’ Bureau: Allergan, Biogen, Intra-Cellular Therapies, Janssen Pharmaceuticals, Neurocrine Biosciences, Otsuka Pharmaceutical Co, Sunovion Pharmaceuticals, Teva Pharmaceuticals

Craig Nelson, MD
Craig Nelson, MD
Leon J. Epstein Endowed Chair, Geriatric Psychiatry
Director, Geriatric Psychiatric Fellowship Program
Director, Geriatric Psychiatry Clinic
UCSF Weill Institute for Neurosciences
University of California, San Francisco
San Francisco, CA

Disclosures: Consultant: Astellas Pharma (macular degeneration), Axsome Therapeutics (depression), Biohaven Pharmaceuticals (anxiety), Janssen Pharmaceuticals (depression, insomnia), Novartis Pharmaceuticals Corporation (depression), Otsuka Pharmaceutical Co (depression), Sunovion Pharmaceuticals (bipolar depression).

Edward V. Nunes, MD
Edward V. Nunes, MD
Professor, Department of Psychiatry
Columbia University Irving Medical Center Research
Psychiatrist
New York State Psychiatric Institute
New York, NY

Disclosures: Edward V. Nunes, MD, has no relevant financial relationships with ineligible companies.

Jennifer L. Payne, MD
Jennifer L. Payne, MD
Associate Professor, Psychiatry and Behavioral Sciences
Associate Professor, Gynecology and Obstetrics
Director, Women’s Mood Disorders Center
Johns Hopkins Medicine
Baltimore, MD

Disclosures: Consultant: Janssen Pharmaceuticals, SAGE Therapeutics; Other: Patent: Epigenetic Biomarkers of Postpartum Depression.

Sheldon H. Preskorn, MD
Sheldon H. Preskorn, MD
Professor, Department of Psychiatry and Behavioral Sciences
University of Kansas School of Medicine–Wichita
Wichita, KS

Disclosures: Consultant: BioXcel Therapeutics, Janssen Pharmaceuticals, Lyndra Therapeutics; Speakers’ Bureau: Eisai, Janssen Pharmaceuticals, Merck & Co, Sunovion Pharmaceuticals.

Gail Erlick Robinson MD, FRCPC, CM, OOnt
Gail Erlick Robinson MD, FRCPC, CM, OOnt
Professor, Adult Psychiatry and Health Systems
Professor, Core Obstetrics and Gynecology
Co-Founder, Women’s Mental Health Program
University of Toronto
Toronto, Canada

Disclosures: Gail Erlick Robinson, MD, FRPC, CM, Oont, has no relevant financial relationships with ineligible companies.

Steven Shoptaw, PhD
Steven Shoptaw, PhD
Professor, Family Medicine and Psychiatry and Biobehavioral Sciences
Director, Center for Behavioral and Addiction Medicine
Vice Chair, Research in Family Medicine
University of California, Los Angeles Health
Los Angeles, CA

Disclosures: Steven Shoptaw, PhD, has no relevant financial relationships with ineligible companies.

Michael E. Thase, MD
Michael E. Thase, MD
Professor, Department of Psychiatry
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Disclosures: Grant Research Support: Acadia Pharmaceuticals, Agency for Healthcare Research and Quality, Alkermes, Allergan, Assurex Health, Avanir Pharmaceuticals, Axsome Therapeutics, Intra-Cellular Therapies, Janssen Pharmaceuticals, Johnson & Johnson, National Institute of Mental Health, Otsuka Pharmaceutical Co, Patient-Centered Outcomes Research Institute, Takeda Pharmaceutical Company; Consultant: Acadia Pharmaceuticals, Agency for Healthcare Research and Quality, Alkermes, Allergan, Assurex Health, Avanir Pharmaceuticals, Axsome Therapeutics, Intra-Cellular Therapies, Janssen Pharmaceuticals, Johnson & Johnson, National Institute of Mental Health, Otsuka Pharmaceutical Co, Patient-Centered Outcomes Research Institute, Takeda Pharmaceutical Company.

Nassima Ait-Daoud Tiouririne, MD
Nassima Ait-Daoud Tiouririne, MD
Professor
Addiction Medicine Fellowship Director
Associate Director, Psychiatry Residency Program
Department of Psychiatry and Neurobehavioral Sciences
Director, Center for Leading-Edge Addiction Research
Medical Director, Ambulatory Psychiatry and Office-Based Opioid Treatment
University of Virginia School of Medicine
Charlottesville, VA

Disclosures: Nassima Ait-Daoud Tiouririne, MD, has no relevant financial relationships with ineligible companies.

Phebe Tucker, MD
Phebe Tucker, MD
Vice Chair, Education
Professor and Arnold and Bess Ungerman Chair in Psychiatry
Robert Glenn Rapp Foundation Presidential Professorship of Medicine
Adult Mental Health Services
Department of Psychiatry and Behavioral Sciences
The University of Oklahoma College of Medicine
Oklahoma City, OK

Disclosures: Phebe Tucker, MD, has no relevant financial relationships with ineligible companies.

Jack L. Turban, MD, MHS
Jack L. Turban, MD, MHS
Chief Fellow, Child and Adolescent Psychiatry
Stanford University School of Medicine
Stanford, CA

Disclosures: Grant Research Support: Pilot Research Award from the American Academy of Child and Adolescent Psychiatry and pharmaceutical partners (Pfizer and Arbor Pharmaceuticals); Consultant: Panorama Global.

J. Eric Vance, MD
J. Eric Vance, MD
Associate Professor, Child Psychiatry
Virginia Tech Carilion School of Medicine
Roanoke, VA

Disclosures: J. Eric Vance, MD, has no relevant financial relationships with ineligible companies.

Karen Dineen Wagner, MD, PhD
Karen Dineen Wagner, MD, PhD
Marie B. Gale Professor and Vice Chair
Department of Psychiatry and Behavioral Sciences
Director, Division of Child and Adolescent Psychiatry
University of Texas Medical Branch
Galveston, TX

Disclosures: Grant Research Support: Doris Duke Charitable Foundation, Klingenstein Third Generation Foundation; Consultant: Axsome Therapeutics.

Mark Zimmerman, MD
Mark Zimmerman, MD
Professor, Psychiatry and Human Behavior
Brown University Medical School
Director, Outpatient Psychiatry and the Partial Hospital Program
Rhode Island Hospital
Director, Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) Project
Providence, RI

Disclosures: Mark Zimmerman has no relevant financial relationships with ineligible companies.

Sidney Zisook, MD
Sidney Zisook, MD
Distinguished Professor of Psychiatry
Director, Residency Training Program
University of California, San Diego
La Jolla, CA

Disclosures: Grant Research Support: Compass.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By